Top

03-08-2017 | Cervical cancer | Article

HPV Vaccination: Are We Meeting Our Targets in Cervical Cancer Prevention?

Journal: Current Obstetrics and Gynecology Reports

Authors: Anna L. Beavis, Anne F. Rositch, Melinda Krakow, Kimberly L. Levinson

Abstract

Purpose of Review

The purpose of this review is to update the reader on the most recent HPV vaccine uptake rates in boys and girls in the United States and to summarize the recent recommendations for vaccination. The review also evaluates a decade of data demonstrating the safety and efficacy of the HPV vaccine and discusses disparities in vaccine uptake in the US. Finally, we will summarize the scope of attempted and proposed interventions to improve vaccine uptake in the United States.

Recent Findings

Topics discussed in this review include the recommendations for the nine-valent HPV vaccine and the two-dose injection regimen. Additionally, many studies reviewed demonstrate continued disparities in HPV vaccine uptake in the US. An update on various interventions to address poor uptake is provided.

Summary

Despite being FDA-approved since 2006, only 42% of US adolescent girls and 28% of boys had completed the HPV vaccine series in 2015, well below the Healthy People 2020 goal of 80%. A decade of data has proven that the vaccine is safe and effective. Physician recommendation is consistently the strongest predictor of vaccine uptake, and initiation and recommendation rates differ by region, race, sexual orientation, and socioeconomic status. Special populations, including sexual minorities and children with chronic medical conditions, have particularly low rates of vaccination, representing addressable missed opportunities for vaccination. Interventions to improve uptake have ranged from education to state mandates, with variable effectiveness. Culturally sensitive, multimodal, tailored interventions to improve uptake may hold the most promise, including the use of novel delivery locations such as pharmacies, schools, and the postpartum visit. This article reviews a decade of data on vaccine safety, efficacy, disparities, and interventions to improve vaccination rates, focusing on the most recent year of published data.

Simard EP, Naishadham D, Saslow D, Jemal A. Age-specific trends in black-white disparities in cervical cancer incidence in the United States: 1975–2009. Gynecol Oncol. 2012;127:611–5. doi:10.1016/j.ygyno.2012.08.021.CrossRefPubMed

Mourad M, Jetmore T, Jategaonkar AA, Moubayed S, Moshier E, Urken ML. Epidemiological trends of head and neck cancer in the United States: a SEER population study. J Oral Maxillofac Surg. 2017; doi:10.1016/j.joms.2017.05.008.

Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339.

Accelerating HPV vaccine uptake: urgency for action to prevent cancer. A report to the President of the United States from the President’s Cancer Panel. Bethesda, MD: National Cancer Institute; 2014.

• Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Curtis CR, MacNeil J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:850–8. doi:10.15585/mmwr.mm6533a4. This article provides the most up-to-date HPV vaccination coverage rates in the United States.CrossRefPubMed

Healthy People 2020 topics and objectives: immunization and infectious diseases. http://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives?topicId=23. Accessed 27 Oct 2015.

Van Damme P, Meijer CJLM, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016;34:4205–12. doi:10.1016/j.vaccine.2016.06.056.CrossRefPubMed

• Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination? Updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016;65:1405–8. doi:10.15585/mmwr.mm6549a5. This article provides the recommendations for the 2-dose vaccine schedule for adolescents under the age of 15, and the use of 9-valent HPV vaccine.CrossRefPubMed

Bailey HH, Chuang LT, duPont NC, Eng C, Foxhall LE, Merrill JK, et al. American Society of Clinical Oncology statement: human papillomavirus vaccination for cancer prevention. J Clin Oncol. 2016;34:1803–12. doi:10.1200/JCO.2016.67.2014.CrossRefPubMed

10.

Committee Opinion No. 704 Summary. Obstet Gynecol. 2017;129:1155–1156. doi: 10.1097/AOG.0000000000002111

11.

Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008;26(Suppl 1):K53–61. doi:10.1016/j.vaccine.2008.06.002.CrossRefPubMedPubMedCentral

12.

Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63:1–30.PubMed

13.

Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–23. doi:10.1056/NEJMoa1405044.CrossRefPubMed

14.

Petrosky E, Bocchini JA, Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–4.PubMed

15.

Vaccine information statement|recent and upcoming changes|VIS|CDC. https://www.cdc.gov/vaccines/hcp/vis/what-is-new.html. Accessed 18 Jun 2017.

16.

•• Gee J, Weinbaum C, Sukumaran L, Markowitz LE. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother. 2016;12:1406–17. doi:10.1080/21645515.2016.1168952. This review comprehensively evaluates published and unpublished data since the release of the 4vHPV vaccine and demonstrates its proven safety.CrossRefPubMedPubMedCentral

17.

Grimaldi-Bensouda L, Rossignol M, Koné-Paut I, Krivitzky A, Lebrun-Frenay C, Clet J, et al. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance. J Autoimmun. 2017;79:84–90. doi:10.1016/j.jaut.2017.01.005.CrossRefPubMed

18.

Moreira ED, Block SL, Ferris D, Giuliano AR, Iversen O-E, Joura EA, et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials. Pediatrics. 2016;138:e20154387. doi:10.1542/peds.2015-4387.CrossRefPubMed

19.

FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen O-E, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.CrossRef

20.

Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63:519–27. doi:10.1093/cid/ciw354.CrossRefPubMedPubMedCentral

21.

Chow EPF, Machalek DA, Tabrizi SN, Danielewski JA, Fehler G, Bradshaw CS, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis. 2017;17:68–77. doi:10.1016/S1473-3099(16)30116-5.CrossRefPubMed

22.

Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137:e20151968. doi:10.1542/peds.2015-1968.CrossRefPubMed

23.

Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States—2008–2012. Vaccine. 2015;33:1608–13. doi:10.1016/j.vaccine.2015.01.084.CrossRefPubMed

24.

D’Addario M, Redmond S, Scott P, Egli-Gany D, Riveros-Balta AX, Henao Restrepo AM, et al. Two-dose schedules for human papillomavirus vaccine: systematic review and meta-analysis. Vaccine. 2017;35:2892–901. doi:10.1016/j.vaccine.2017.03.096.CrossRefPubMed

25.

Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica vaccine and PATRICIA trials. Lancet Oncol. 2015;16:775–86. doi:10.1016/S1470-2045(15)00047-9.CrossRefPubMedPubMedCentral

26.

Daley MF, Crane LA, Markowitz LE, Black SR, Beaty BL, Barrow J, et al. Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure. Pediatrics. 2010;126:425–33. doi:10.1542/peds.2009-3500.CrossRefPubMed

27.

Mohammed KA, Geneus CJ, Osazuwa-Peters N, Adjei Boakye E, Tobo BB, Burroughs TE. Disparities in provider recommendation of human papillomavirus vaccination for U.S. adolescents. J Adolesc Health. 2016;59:592–8. doi:10.1016/j.jadohealth.2016.06.005.CrossRefPubMed

28.

Kepka D, Spigarelli MG, Warner EL, Yoneoka Y, McConnell N, Balch A. Statewide analysis of missed opportunities for human papillomavirus vaccination using vaccine registry data. Papillomavirus Res. 2016;2:128–32. doi:10.1016/j.pvr.2016.06.002.CrossRefPubMed

29.

Moss JL, Gilkey MB, Rimer BK, Brewer NT. Disparities in collaborative patient-provider communication about human papillomavirus (HPV) vaccination. Hum Vaccin Immunother. 2016;12:1476–83. doi:10.1080/21645515.2015.1128601.CrossRefPubMedPubMedCentral

30.

Grant SR, Walker GV, Guadagnolo BA, Koshy M, Allen PK, Mahmood U. Variation in insurance status by patient demographics and tumor site among nonelderly adult patients with cancer. Cancer. 2015;121:2020–8. doi:10.1002/cncr.29120.CrossRefPubMedPubMedCentral

31.

Ward KK, Shah NR, Saenz CC, McHale MT, Alvarez EA, Plaxe SC. Changing demographics of cervical cancer in the United States (1973–2008). Gynecol Oncol. 2012;126:330–3. doi:10.1016/j.ygyno.2012.05.035.CrossRefPubMed

32.

Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer. 2014;120:2032–8. doi:10.1002/cncr.28548.CrossRefPubMedPubMedCentral

33.

Beavis AL, Gravitt PE, Rositch AF. Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer. 2017;123:1044–50. doi:10.1002/cncr.30507.CrossRefPubMed

34.

Lefkowitz ES, Kelly KM, Vasilenko SA, Maggs JL. Correlates of human papillomavirus vaccination among female university students. Women Health. 2014;54:487–501. doi:10.1080/03630242.2014.903552.CrossRefPubMedPubMedCentral

35.

Kramer MR, Dunlop AL. Inter-state variation in human papilloma virus vaccine coverage among adolescent girls in the 50 US states, 2007. Matern Child Health J. 2012;16(Suppl 1):S102–10. doi:10.1007/s10995-012-0999-6.CrossRefPubMed

36.

Laz TH, Rahman M, Berenson AB. Human papillomavirus vaccine uptake among 18- to 26-year-old women in the United States: National Health Interview Survey, 2010. Cancer. 2013;119:1386–92. doi:10.1002/cncr.27894.CrossRefPubMed

37.

Fisher H, Trotter CL, Audrey S, MacDonald-Wallis K, Hickman M. Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis. Int J Epidemiol. 2013;42:896–908. doi:10.1093/ije/dyt049.CrossRefPubMedPubMedCentral

38.

National, state, and local area vaccination coverage among adolescents aged 13–17 years—United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:997–1001.

39.

Cheruvu VK, Bhatta MP, Drinkard LN. Factors associated with parental reasons for “no-intent” to vaccinate female adolescents with human papillomavirus vaccine: National Immunization Survey—Teen 2008–2012. BMC Pediatr. 2017;17:52. doi:10.1186/s12887-017-0804-1.CrossRefPubMedPubMedCentral

40.

Burger EA, Lee K, Saraiya M, Thompson TD, Chesson HW, Markowitz LE, et al. Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines. Cancer. 2016;122:2057–66. doi:10.1002/cncr.30007.CrossRefPubMedPubMedCentral

41.

Reiter PL, McRee A-L. HPV infection among a population-based sample of sexual minority women from USA. Sex Transm Infect. 2017;93:25–31. doi:10.1136/sextrans-2016-052536.CrossRefPubMed

42.

Agénor M, Peitzmeier SM, Gordon AR, Charlton BM, Haneuse S, Potter J, et al. Sexual orientation identity disparities in human papillomavirus vaccination initiation and completion among young adult US women and men. Cancer Causes Control. 2016;27:1187–96. doi:10.1007/s10552-016-0796-4.CrossRefPubMed

43.

McRee A-L, Katz ML, Paskett ED, Reiter PL. HPV vaccination among lesbian and bisexual women: findings from a national survey of young adults. Vaccine. 2014;32:4736–42. doi:10.1016/j.vaccine.2014.07.001.CrossRefPubMedPubMedCentral

44.

Charlton BM, Reisner SL, Agénor M, Gordon AR, Sarda V, Austin SB. Sexual orientation disparities in human papillomavirus vaccination in a longitudinal cohort of U.S. males and females. LGBT Heal. 2017;4:202–9. doi:10.1089/lgbt.2016.0103.CrossRef

45.

Gorbach PM, Cook R, Gratzer B, Collins T, Parrish A, Moore J, et al. Human papillomavirus vaccination among young men who have sex with men and transgender women in 2 US cities, 2012–2014. Sex Transm Dis. 2017;44:436–41. doi:10.1097/OLQ.0000000000000626.CrossRefPubMed

46.

Sainato R, Flores M, Malloy A, Geaney C, Rajnik M, Ottolini M, et al. Health maintenance deficits in a fully insured population of adolescents with chronic medical conditions. Clin Pediatr (Phila). 2017;56:512–8. doi:10.1177/0009922816678183.CrossRef

47.

Praditpornsilpa K, Kingwatanakul P, Deekajorndej T, Rianthavorn P, Susantitaphong P, Katavetin P, et al. Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD. Nephrol Dial Transplant. 2016;32:gfv444. doi:10.1093/ndt/gfv444.CrossRef

48.

Hofstetter AM, Lappetito L, Stockwell MS, Rosenthal SL. Human papillomavirus vaccination of adolescents with chronic medical conditions: a national survey of pediatric subspecialists. J Pediatr Adolesc Gynecol. 2017;30:88–95. doi:10.1016/j.jpag.2016.08.005.CrossRefPubMed

49.

Wilson AR, Hashibe M, Bodson J, Gren LH, Taylor BA, Greenwood J, et al. Factors related to HPV vaccine uptake and 3-dose completion among women in a low vaccination region of the USA: an observational study. BMC Womens Health. 2016;16:41. doi:10.1186/s12905-016-0323-5.CrossRefPubMedPubMedCentral

50.

Johnson KL, Lin M-Y, Cabral H, Kazis LE, Katz IT. Variation in human papillomavirus vaccine uptake and acceptability between female and male adolescents and their caregivers. J Community Health. 2017;42:522–32. doi:10.1007/s10900-016-0284-5.CrossRefPubMedPubMedCentral

51.

Fu LY, Zimet GD, Latkin CA, Joseph JG. Associations of trust and healthcare provider advice with HPV vaccine acceptance among African American parents. Vaccine. 2017;35:802–7. doi:10.1016/j.vaccine.2016.12.045.CrossRefPubMed

52.

Gilkey MB, Malo TL, Shah PD, Hall ME, Brewer NT. Quality of physician communication about human papillomavirus vaccine: findings from a national survey. Cancer Epidemiol Biomark Prev. 2015;24:1673–9. doi:10.1158/1055-9965.EPI-15-0326.CrossRef

53.

Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT. Provider communication and HPV vaccination: the impact of recommendation quality. Vaccine. 2016;34:1187–92. doi:10.1016/j.vaccine.2016.01.023.CrossRefPubMedPubMedCentral

54.

Burdette AM, Webb NS, Hill TD, Jokinen-Gordon H. Race-specific trends in HPV vaccinations and provider recommendations: persistent disparities or social progress? Public Health. 2017;142:167–76. doi:10.1016/j.puhe.2016.07.009.CrossRefPubMed

55.

Gerend MA, Shepherd MA, Lustria MLA, Shepherd JE. Predictors of provider recommendation for HPV vaccine among young adult men and women: findings from a cross-sectional survey: table 1. Sex Transm Infect. 2016;92:104–7. doi:10.1136/sextrans-2015-052088.CrossRefPubMed

56.

Wheldon CW, Sutton SK, Fontenot HB, Quinn GP, Giuliano AR, Vadaparampil ST. Physician communication practices as a barrier to risk-based HPV vaccine uptake among men who have sex with men. J Cancer Educ. 2017; doi:10.1007/s13187-017-1223-6.

57.

Rutten LJF, St. Sauver JL, Beebe TJ, Wilson PM, Jacobson DJ, Fan C, et al. Clinician knowledge, clinician barriers, and perceived parental barriers regarding human papillomavirus vaccination: association with initiation and completion rates. Vaccine. 2017;35:164–9. doi:10.1016/j.vaccine.2016.11.012.CrossRefPubMed

58.

Kulczycki A, Qu H, Shewchuk R. Recommend, but also discuss: different patterns of physician-perceived barriers to discussing HPV vaccination and their association with vaccine administration in 11–12 year-old girls. Matern Child Health J. 2016;20:2539–47. doi:10.1007/s10995-016-2079-9.CrossRefPubMed

59.

Krakow M, Beavis A, Cosides O, Rositch AF. Characteristics of adolescents lacking provider-recommended human papillomavirus vaccination. J Adolesc Health. 2017;60:619–22. doi:10.1016/j.jadohealth.2016.11.028.CrossRefPubMed

60.

Berenson AB, Hirth JM, Fuchs EL. US medical students’ willingness to offer the HPV vaccine by vaccination status. Vaccine. 2017; doi:10.1016/j.vaccine.2017.01.028.

61.

Afonso NM, Kavanagh MJ, Swanberg SM, Schulte JM, Wunderlich T, Lucia VC. Will they lead by example? Assessment of vaccination rates and attitudes to human papilloma virus in millennial medical students. BMC Public Health. 2017;17:35. doi:10.1186/s12889-016-3969-x.CrossRefPubMedPubMedCentral

62.

Mills J, Van Winkle P, Shen M, Hong C, Hudson S. Physicians’, nurses’, and medical assistants’ perceptions of the human papillomavirus vaccine in a large integrated health care system. Perm J. 2016; doi:10.7812/TPP/15-205.

63.

Bratic JS, Seyferth ER, Bocchini JA. Update on barriers to human papillomavirus vaccination and effective strategies to promote vaccine acceptance. Curr Opin Pediatr. 2016;28:407–12. doi:10.1097/MOP.0000000000000353.CrossRefPubMed

64.

Fu LY, Bonhomme L-A, Cooper SC, Joseph JG, Zimet GD. Educational interventions to increase HPV vaccination acceptance: a systematic review. Vaccine. 2014;32:1901–20. doi:10.1016/j.vaccine.2014.01.091.CrossRefPubMedPubMedCentral

65.

Niccolai LM, Hansen CE. Practice- and community-based interventions to increase human papillomavirus vaccine coverage: a systematic review. JAMA Pediatr. 2015;169:686–92. doi:10.1001/jamapediatrics.2015.0310.CrossRefPubMedPubMedCentral

66.

Francis DB, Cates JR, Wagner KPG, Zola T, Fitter JE, Coyne-Beasley T. Communication technologies to improve HPV vaccination initiation and completion: a systematic review. Patient Educ Couns. 2017; doi:10.1016/j.pec.2017.02.004.

67.

U.S. Preventative Services Task Force. The community guide—summary—vaccination: standing orders.

68.

Garland SM. The Australian experience with the human papillomavirus vaccine. Clin Ther. 2014;36:17–23. doi:10.1016/j.clinthera.2013.12.005.CrossRefPubMed

69.

Middleman AB, Won T, Auslander B, Misra S, Short M. HPV vaccine uptake in a school-located vaccination program. Hum Vaccin Immunother. 2016;12:2872–4. doi:10.1080/21645515.2016.1208326.CrossRefPubMedPubMedCentral

70.

Daley MF, Kempe A, Pyrzanowski J, Vogt TM, Dickinson LM, Kile D, et al. School-located vaccination of adolescents with insurance billing: cost, reimbursement, and vaccination outcomes. J Adolesc Health. 2014;54:282–8. doi:10.1016/j.jadohealth.2013.12.011.CrossRefPubMed

71.

Rosen BL, DiClemente R, Shepard AL, Wilson KL, Fehr SK. Factors associated with school nurses? HPV vaccine attitudes for school-aged youth. Psychol Health Med. 2017;22:535–45. doi:10.1080/13548506.2016.1173710.CrossRefPubMed

72.

Calo WA, Gilkey MB, Shah P, Marciniak MW, Brewer NT. Parents’ willingness to get human papillomavirus vaccination for their adolescent children at a pharmacy. Prev Med (Baltim). 2017;99:251–6. doi:10.1016/j.ypmed.2017.02.003.CrossRef

73.

Smith JS, Islam J, Gruber J, Lockhart A, Kunwar M, Wilson S, et al. Opportunities and challenges of adolescent and adult vaccination administration within pharmacies in the United States. Biomed Inform Insights. 2017;9:1178222617692538. doi:10.1177/1178222617692538.CrossRefPubMedPubMedCentral

74.

Scherer EM, Smith RA, Gallego DF, Carter JJ, Wipf GC, Hoyos M, et al. A single human papillomavirus vaccine dose improves B cell memory in previously infected subjects. EBioMedicine. 2016;10:55–64. doi:10.1016/j.ebiom.2016.06.042.CrossRefPubMedPubMedCentral

75.

Wright JD, Govindappagari S, Pawar N, Cleary K, Burke WM, Devine PC, et al. Acceptance and compliance with postpartum human papillomavirus vaccination. Obstet Gynecol. 2012;120:771–82. doi:10.1097/AOG.0b013e31826afb56.CrossRefPubMed

76.

Gross TT, Rahman M, M. Wright A, M. Hirth J, Sarpong KO, Rupp RE, et al. Implementation of a postpartum HPV vaccination program in a Southeast Texas hospital: a qualitative study evaluating health care provider acceptance. Matern Child Health J. 2016;20:154–63. doi:10.1007/s10995-016-2030-0.CrossRefPubMed

77.

National Conference of State Legislatures HPV Vaccine: State Legislation and Statutes. http://www.ncsl.org/research/health/hpv-vaccine-state-legislation-and-statutes.aspx. Accessed 9 Nov 2015.

78.

Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Singleton JA, Curtis CR, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64:784–92.CrossRefPubMed

79.

Pitts MJ, Adams Tufts K. Implications of the Virginia human papillomavirus vaccine mandate for parental vaccine acceptance. Qual Health Res. 2013;23:605–17. doi:10.1177/1049732312470871.CrossRefPubMed

80.

Perkins RB, Lin M, Wallington SF, Hanchate AD. Impact of school-entry and education mandates by states on HPV vaccination coverage: analysis of the 2009–2013 National Immunization Survey-Teen. Hum Vaccin Immunother. 2016;12:1615–22. doi:10.1080/21645515.2016.1150394.CrossRefPubMedPubMedCentral

81.

Garland SM, Eundem FA, Rcpa F. The Australian experience with the human papillomavirus vaccine. Clin Ther. 2014;36:17–23. doi:10.1016/j.clinthera.2013.12.005.CrossRefPubMed

82.

Strategies for Increasing Adult Vaccination Rates|CDC. https://www.cdc.gov/vaccines/hcp/adults/for-practice/increasing-vacc-rates.html. Accessed 25 Jun 2017.

Medicine Matters Oncology

Abstract

Purpose of Review

Recent Findings

Summary